BACKGROUND: Several authors have demonstrated a trend toward the under-treatment of elderly and very elderly women with breast cancer. This study was undertaken to determine the impact of under-treatment of breast cancer in women age 80 and older. METHODS: A retrospective chart review of all patients 80 years and older with a newly diagnosed breast cancer at the MD Anderson Cancer Center, Houston, TX, between September 1, 1989 and September 1, 2004 was performed. Data extracted from charts included patient demographics, comorbidity, treatments recommended, treatments received, complications of therapy, disease recurrence and disease related death. Treatments undertaken were analyzed in the context of accepted therapy at the time of diagnosis. RESULTS: Two hundred twelve patients were identified. The median age was 83.5 years (range 80-97). Overall survival in the entire cohort was 7.28 years with a median follow up of 4 years for patients still alive at the end of the study period. Fifty seven percent of patients were under-treated according to institutional and national guidelines. Women who underwent hormonal therapy only demonstrated decreased disease specific survival (P<0.001 respectively) compared with patients who received multi-modality therapy. Women who underwent partial mastectomy without radiation treatment experienced a significant increase in local regional recurrence (P=0.045). There was an association of increased disease specific survival in patients who had surgical lymph node evaluation compared to those who did not (P=0.04). CONCLUSIONS: Outcomes are compromised in very elderly women with breast cancer in whom less than complete combined modality treatment is undertaken. With the previously demonstrated safety of radiation therapy, hormonal therapy and surgery in the very elderly population, multi-modality therapy should not be routinely withheld in patients in this age category.
BACKGROUND: Several authors have demonstrated a trend toward the under-treatment of elderly and very elderly women with breast cancer. This study was undertaken to determine the impact of under-treatment of breast cancer in women age 80 and older. METHODS: A retrospective chart review of all patients 80 years and older with a newly diagnosed breast cancer at the MD Anderson Cancer Center, Houston, TX, between September 1, 1989 and September 1, 2004 was performed. Data extracted from charts included patient demographics, comorbidity, treatments recommended, treatments received, complications of therapy, disease recurrence and disease related death. Treatments undertaken were analyzed in the context of accepted therapy at the time of diagnosis. RESULTS: Two hundred twelve patients were identified. The median age was 83.5 years (range 80-97). Overall survival in the entire cohort was 7.28 years with a median follow up of 4 years for patients still alive at the end of the study period. Fifty seven percent of patients were under-treated according to institutional and national guidelines. Women who underwent hormonal therapy only demonstrated decreased disease specific survival (P<0.001 respectively) compared with patients who received multi-modality therapy. Women who underwent partial mastectomy without radiation treatment experienced a significant increase in local regional recurrence (P=0.045). There was an association of increased disease specific survival in patients who had surgical lymph node evaluation compared to those who did not (P=0.04). CONCLUSIONS: Outcomes are compromised in very elderly women with breast cancer in whom less than complete combined modality treatment is undertaken. With the previously demonstrated safety of radiation therapy, hormonal therapy and surgery in the very elderly population, multi-modality therapy should not be routinely withheld in patients in this age category.
Authors: Mara A Schonberg; Robyn L Birdwell; Brittany L Bychkovsky; Lindsay Hintz; Valerie Fein-Zachary; Michael D Wertheimer; Rebecca A Silliman Journal: Breast Cancer Res Treat Date: 2014-03-31 Impact factor: 4.872
Authors: Jennifer K Plichta; Samantha M Thomas; Rebecca Vernon; Oluwadamilola M Fayanju; Laura H Rosenberger; Terry Hyslop; E Shelley Hwang; Rachel A Greenup Journal: Breast Cancer Res Treat Date: 2020-01-24 Impact factor: 4.872
Authors: Nina Ommundsen; Torgeir B Wyller; Arild Nesbakken; Marit S Jordhøy; Arne Bakka; Eva Skovlund; Siri Rostoft Journal: Oncologist Date: 2014-10-29
Authors: Vanessa B Sheppard; Leigh Anne Faul; George Luta; Jonathan D Clapp; Rachel L Yung; Judy Huei-Yu Wang; Gretchen Kimmick; Claudine Isaacs; Michelle Tallarico; William T Barry; Brandelyn N Pitcher; Clifford Hudis; Eric P Winer; Harvey J Cohen; Hyman B Muss; Arti Hurria; Jeanne S Mandelblatt Journal: J Clin Oncol Date: 2014-06-16 Impact factor: 44.544
Authors: Charlotte E Joslin; Katherine C Brewer; Faith G Davis; Kent Hoskins; Caryn E Peterson; Heather A Pauls Journal: Gynecol Oncol Date: 2014-08-28 Impact factor: 5.482